The 150 most important questions in cancer research and clinical oncology series: questions 86-93 : Edited by Chinese Journal of Cancer.
10.1186/s40880-018-0266-3
- Author:
Chinese Journal of Cancer
- Collective Name:Chinese Journal of Cancer
- Publication Type:Editorial
- Keywords:
Animal model;
Hepatitis B virus-associated cancer;
Mimic immunotherapy;
Molecular event;
Non-hepatocellular cancer;
Oral cancer;
Postoperative radiotherapy;
Prophylactic therapy;
Supportive care;
Survival;
Tumor genome;
Tumor metabolism
- MeSH:
Humans;
Medical Oncology;
education;
Neoplasms;
genetics;
Research
- From:Chinese Journal of Cancer
2018;37(1):1-1
- CountryChina
- Language:English
-
Abstract:
Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which spark diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 8 more questions are presented as follows. Question 86. In which circumstances is good supportive care associated with a survival advantage in patients with cancer? Question 87. Can we develop animal models to mimic immunotherapy response of cancer patients? Question 88. What are the mechanisms underlying hepatitis B virus-associated non-hepatocellular cancers? Question 89. Can we more precisely target tumor metabolism by identifying individual patients who would benefit from the treatment? Question 90. What type of cranial irradiation-based prophylactic therapy combination can dramatically improve the survival of patients with extensive small-cell lung cancer? Question 91. How can postoperative radiotherapy prolong overall survival of the patients with resected pIIIA-N2 non-small cell lung cancer? Question 92. What are the key molecular events that drive oral leukoplakia or erythroplakia into oral cancer? Question 93. How could we track the chemotherapeutics-driven evolution of tumor genome in non-small cell lung cancer for more effective treatment?
